Uncategorized
Vera Therapeutics (VERA) Stock; Surges 7% as FDA Clears Trutakna for Rare Kidney Disease
TLDRs; Vera Therapeutics shares climbed more than 7% after the FDA granted accelerated approval to Trutakna for primary IgA nephropathy patients. Trutakna is the first approved therapy designed to target both BAFF and APRIL, key […]
